Cancer Cytopathology opens salivary guide

Salivary gland cytology is one of those corners of pathology where the stakes are bigger than the sample. The test is usually a fine-needle aspiration — a few cells, not a whole tumor. But surgeons still need a report they can act on. That is why this new open-access Cancer Cytopathology paper matters: it walks through how standardized reporting systems handle some of the weirdest salivary tumors, especially soft-tissue and bone lesions that do not fit neatly into older habits of description. ### What is the actual problem here? A salivary gland FNA often gives you limited material, and salivary tumors are famously diverse. Different labs have historically used different wording, which makes one report hard to compare with another and makes management less predictable. The whole point of a reporting system is to turn a messy descriptive impression into a category that carries an implied level of cancer risk and a practical next step. (acsjournals.onlinelibrary.wiley.com) ### What is the Milan system? The Milan System for Reporting Salivary Gland Cytopathology is the main standardized framework for salivary gland FNA. It launched in 2018 with six diagnostic categories spanning nondiagnostic, non-neoplastic, atypia, neoplasm, suspicious for malignancy, and malignant. Each category is meant to come with a risk of malignancy and a management path, which is the useful part — not just naming cells, but helping decide what to do next. (acsjournals.onlinelibrary.wiley.com) ### What changed in Milan recently? The system already got a major refresh. Its second edition came out in July 2023, refining malignancy-risk estimates with newer meta-analyses, adding more on imaging, ancillary testing, and updated nomenclature. That matters because salivary cytology is not static — molecular testing and imaging now shape interpretation more than they did when the first atlas appeared. (acsjournals.onlinelibrary.wiley.com) ### So what is the IAC–IARC–WHO piece? That is a broader WHO-linked family of cytopathology reporting systems. For this paper, the relevant comparison is the WHO reporting system for soft tissue cytopathology — a framework built to classify tumors from the cytopathologist’s point of view and standardize practice across sites. Basically, Milan is salivary-specific, while the IAC–IARC–WHO approach can be useful when a salivary lesion behaves more like a soft-tissue or bone tumor than a classic salivary epithelial one. (acsjournals.onlinelibrary.wiley.com) ### Why are soft-tissue and bone tumors the hard cases? Because they are rare, morphologically odd, and easy to undersample. A salivary mass can turn out not to be one of the common epithelial tumors that cytopathologists expect. When that happens, a free-text report can get vague fast. Category-based systems force the report to answer the clinical question more directly — benign-looking, indeterminate, suspicious, or malignant — even when the exact subtype still needs surgery, histology, or molecular workup. (publications.iarc.who.int) ### Does Milan actually hold up in practice? Pretty well. A recent meta-analysis of prospective studies found the system works well in real-world FNA practice, with 83.1% sensitivity and 98.4% specificity overall. The malignant category carried a 97.0% risk of malignancy in prospective data, while suspicious for malignancy came in at 86.0%. Those numbers are why clinicians care about the label. (acsjournals.onlinelibrary.wiley.com) ### Why does this help beyond the pathologist? Because the report becomes a shared language. Surgeons can plan how aggressive an operation should be. Radiologists can line imaging up with the cytology category. Molecular labs know which indeterminate cases may need ancillary testing. And when a patient moves between hospitals, the meaning of the diagnosis is less likely to get lost in translation. ASCO’s salivary malignancy guideline already endorses FNA biopsy and the Milan risk-stratification scheme. (acsjournals.onlinelibrary.wiley.com) ### Bottom line? This is not a flashy breakthrough. It is a practical one. The new paper is useful because it shows how to apply standardized reporting when salivary gland aspirates get weird — which is exactly when clarity matters most. (acsjournals.onlinelibrary.wiley.com 1) (acsjournals.onlinelibrary.wiley.com 2)